HCW Biologics Inc. (HCWB) Financial Statements (2024 and earlier)

Company Profile

Business Address 2929 N COMMERCE PKWY
MIRAMAR, FL 33025
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,59511,22117,40828,23832,06226,224
Cash and cash equivalents3,59511,2217,44918,39022,32626,224
Short-term investments   9,9599,8489,736 
Receivables1,536710707253418356
Prepaid expense1,0421,7421,3571,1331,3951,922
Other current assets231175327317196206
Other undisclosed current assets      
Total current assets:6,40413,84819,79929,94034,07128,708
Noncurrent Assets
Operating lease, right-of-use asset  70111   
Property, plant and equipment20,45314,78112,62311,74110,80510,958
Long-term investments and receivables1,6001,6001,6001,6001,60011,269
Long-term investments1,6001,6001,6001,6001,60011,269
Other noncurrent assets57138211253334419
Other undisclosed noncurrent assets  5,1805,139   
Total noncurrent assets:22,10921,76819,68413,59412,73822,645
TOTAL ASSETS:28,51435,61639,48343,53546,80951,353
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,6002,3002,4003,4001,700883
Accounts payable6,1673,1542,1161,1651,2261,410
Other undisclosed accounts payable and accrued liabilities(3,567)(854)2842,235474(528)
Deferred revenue 1,800   1,800 
Debt 119118976838,273 
Other undisclosed current liabilities4,2282,9992,0411,054(38,817)1,410
Total current liabilities:8,7485,4174,5384,5222,9562,293
Noncurrent Liabilities
Long-term debt and lease obligation:      57
Liabilities, other than long-term debt 147  714 
Deferred income tax liabilities 147     
Operating lease, liability    71457
Other undisclosed noncurrent liabilities6,1576,3336,3606,3866,4106,391
Total noncurrent liabilities:6,3046,3336,3606,3946,4246,505
Total liabilities:15,05211,74910,89810,9169,3818,798
Equity
Equity, attributable to parent13,46223,86728,58632,61937,42942,555
Common stock444444
Additional paid in capital83,99083,71583,49583,22482,96382,671
Accumulated deficit(70,532)(59,852)(54,913)(50,609)(45,538)(40,119)
Total equity:13,46223,86728,58632,61937,42942,555
TOTAL LIABILITIES AND EQUITY:28,51435,61639,48343,53546,80951,353

Income Statement (P&L) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Revenues1,324853623421,3421,809
Cost of revenue(1,071)(678)(502)(29)(1,073)(1,447)
Gross profit:25317512013268362
Operating expenses(11,021)(5,253)(4,631)(5,373)(5,936)(4,381)
Operating loss:(10,768)(5,078)(4,511)(5,361)(5,667)(4,020)
Interest and debt expense 1(96)(96)(93)  
Other undisclosed loss from continuing operations before equity method investments, income taxes     (127) 
Loss from continuing operations before equity method investments, income taxes:(10,767)(5,173)(4,606)(5,454)(5,794)(4,020)
Other undisclosed income from continuing operations before income taxes 1,006   305 
Loss from continuing operations:(9,761)(5,173)(4,606)(5,454)(5,489)(4,020)
Loss before gain (loss) on sale of properties:(4,020)
Net loss:(9,761)(5,173)(4,606)(5,454)(5,489)(4,020)
Other undisclosed net income (loss) attributable to parent(920)23530238370105
Net loss available to common stockholders, diluted:(10,681)(4,939)(4,304)(5,071)(5,419)(3,914)

Comprehensive Income ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net loss:(9,761)(5,173)(4,606)(5,454)(5,489)(4,020)
Comprehensive loss, net of tax, attributable to parent:(9,761)(5,173)(4,606)(5,454)(5,489)(4,020)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: